Hyperkalemic cardioplegia-induced myocyte swelling and contractile dysfunction: prevention by diazoxide

Shinichi Mizutani1, Ashraf S Al-Dadah, Jeffrey B Bloch

  • 1Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110-1013, USA.

Insights

Diazoxide, an adenosine triphosphate-sensitive potassium channel (KATP) opener, prevented myocyte swelling and contractility reduction caused by hyperkalemic cardioplegia. This protective effect occurred independently of KATP channel blockade, suggesting a novel mechanism for maintaining cell volume homeostasis.

Area of Science:

  • Cardiology
  • Cell Physiology
  • Pharmacology

Background:

  • Hyperkalemic cardioplegia induces myocyte swelling and reduced contractility, contributing to myocardial stunning.
  • Adenosine triphosphate-sensitive potassium channel (KATP) openers show potential in mitigating myocardial stunning.

Purpose of the Study:

  • To investigate if a KATP opener, diazoxide, could prevent myocyte swelling and contractility loss induced by hyperkalemic cardioplegia.
  • To explore the role of KATP channels in mediating these protective effects.

Main Methods:

  • Isolated rabbit myocytes were exposed to various solutions, including hyperkalemic cardioplegia (St. Thomas's solution at 9 degrees C) with or without diazoxide and KATP blockers (HMR 1098, 5-hydroxydeconoate).
  • Myocyte volume and contractility were measured using videomicroscopy and video-based edge detection before and after cold cardioplegia exposure.

Main Results:

  • Hyperkalemic cardioplegia significantly increased myocyte swelling and decreased contractility (p < 0.05).
  • Diazoxide completely prevented myocyte swelling (p < 0.0001) and preserved contractility (p < 0.05).
  • The effects of diazoxide were not altered by the addition of KATP channel blockers HMR 1098 or 5-hydroxydeconoate.

Conclusions:

  • Diazoxide effectively prevented myocyte swelling and preserved contractility during hyperkalemic cardioplegia.
  • The protective mechanism of diazoxide appears independent of direct KATP channel opening.
  • Myocyte swelling is implicated as a key factor in myocardial stunning, and diazoxide may offer cardioprotection via a non-KATP channel pathway.
Abstract

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...